NKTX Nkarta

Nkarta to Participate at Upcoming Investor Conferences

Nkarta to Participate at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at two upcoming investor conferences:

22nd Annual Needham Virtual Healthcare Conference

April 17, 2023

3:00 p.m. ET – fireside chat

Canaccord Genuity Horizons in Oncology Virtual Conference

April 20, 2023

3:00 p.m. ET – panel discussion

A simultaneous webcast of each event will be available on the Investors section of Nkarta’s website, , and a replay will be archived on the website for approximately 90 days.

About Nkarta

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for patients with cancer. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at .

Nkarta Media/Investor Contact:

Greg Mann

Nkarta, Inc.



EN
13/04/2023

Underlying

NKTXNkarta

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nkarta

 PRESS RELEASE
Free
NKTX NKARTA

Nkarta Announces Poster Presentation at Upcoming American College of R...

Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced it will be presenting a poster this Sunday in Chicago at the American College of Rheumatology (ACR) Convergence 2025 meeting. Nkarta will present clinical data showing that the company’s investigational therapy, NKX019, achieved robust pathogenic B-...

2m 1 EN
 PRESS RELEASE
Free
NKTX NKARTA

Nkarta to Participate in a September Investor Conference

Nkarta to Participate in a September Investor Conference SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 9, 20258:30 a.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, , and a replay will be archived on the website for approximately 90 ...

September 2, 2025 1 EN
 PRESS RELEASE
Free
NKTX NKARTA

Nkarta Reports Second Quarter 2025 Financial Results and Corporate Hig...

Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights Initial update for NKX019 in multiple autoimmune indications expected in second half of 2025Cash balance of $334.0 million on June 30, 2025, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter and year ended June 30, 2025. “We rema...

August 12, 2025 1 EN
 PRESS RELEASE
Free
NKTX NKARTA

Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series

Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series SOUTH SAN FRANCISCO, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the H.C. Wainwright “HCW@Home” Series. H.C Wainwright “HCW@Home with Nkarta, Inc.”July 30, 202511:00 a.m. ET – fireside chat Register for the webcast . A simultaneous webcast of the event will also be available on the Investors section of Nkarta’s website, , and a replay will be archived on the ...

July 23, 2025 1 EN
 PRESS RELEASE
Free
NKTX NKARTA

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Comp...

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced the appointment of Shawn Rose, M.D. Ph.D., as its next Chief Medical Officer (CMO) and Head of Research and Development (R&D) starting on June 23, 2025. He replaces David R. Shook, M.D., who will be stepping down from the role to pur...

June 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch